Home LiteratureArticle Details
PMID: 29320521 Published · epublish English Journal Article Research Support, Non-U.S. Gov't

CD8+ T cell infiltration in breast and colon cancer: A histologic and statistical analysis.

PloS one ·Vol. 13 ·No. 1 ·2018-00-00 ·Pages e0190158

Ziai J, Gilbert HN, Foreman O, Eastham-Anderson J, Chu F, Huseni M, Kim JM

Abstract

The prevalence of cytotoxic tumor infiltrating lymphocytes (TILs) has demonstrated prognostic value in multiple tumor types. In particular, CD8 counts (in combination with CD3 and CD45RO) have been shown to be superior to traditional UICC staging in colon cancer patients and higher total CD8 counts have been associated with better survival in breast cancer patients. However, immune infiltrate heterogeneity can lead to potentially significant misrepresentations of marker prevalence in routine histologic sections. We examined step sections of breast and colorectal cancer samples for CD8+ T cell prevalence by standard chromogenic immunohistochemistry to determine marker variability and inform practice of T cell biomarker assessment in formalin-fixed, paraffin-embedded (FFPE) tissue samples. Stained sections were digitally imaged and CD8+ lymphocytes within defined regions of interest (ROI) including the tumor and surrounding stroma were enumerated. Statistical analyses of CD8+ cell count variability using a linear model/ANOVA framework between patients as well as between levels within a patient sample were performed. Our results show that CD8+ T-cell distribution is highly homogeneous within a standard tissue sample in both colorectal and breast carcinomas. As such, cytotoxic T cell prevalence by immunohistochemistry on a single level or even from a subsample of biopsy fragments taken from that level can be considered representative of cytotoxic T cell infiltration for the entire tumor section within the block. These findings support the technical validity of biomarker strategies relying on CD8 immunohistochemistry.

MeSH Terms
Adult Aged Aged, 80 and over Biopsy/methods Breast Neoplasms/immunology,pathology CD8-Positive T-Lymphocytes/immunology,pathology Carcinoma/immunology,pathology Colorectal Neoplasms/immunology,pathology Computer Simulation Cytotoxicity, Immunologic Female Histological Techniques Humans Image Processing, Computer-Assisted Lymphocyte Count Lymphocytes, Tumor-Infiltrating/immunology,pathology Male Middle Aged Prognosis ROC Curve T-Lymphocyte Subsets/immunology,pathology T-Lymphocytes, Cytotoxic/immunology,pathology Tumor Microenvironment
Authors & Affiliations
7 authors, click to expand affiliations / ORCID
Ziai James ORCID
Department of Pathology, Genentech, Inc., South San Francisco, California, United States of America.
Gilbert Houston N
Department of Biostatistics, Genentech, Inc., South San Francisco, California, United States of America.
Foreman Oded
Department of Pathology, Genentech, Inc., South San Francisco, California, United States of America.
Eastham-Anderson Jeffrey
Department of Pathology, Genentech, Inc., South San Francisco, California, United States of America.
Chu Felix
Department of Pathology, Genentech, Inc., South San Francisco, California, United States of America.
Huseni Mahrukh
Department of Oncology Biomarker Development, Genentech, Inc., South San Francisco, California, United States of America.
Kim Jeong M
Department of Cancer Immunology, Genentech, Inc., South San Francisco, California, United States of America.
References (57)
57 references, click to expand
  1. Immunocytochemical analysis of the cellular infiltrate in primary regressing and non-regressing malignant melanoma.
    J Invest Dermatol. 1991 Aug;97(2):197-202 PMID: 1712819
  2. Quantitative and pathologist-read comparison of the heterogeneity of programmed death-ligand 1 (PD-L1) expression in non-small cell lung cancer.
    Mod Pathol. 2017 Mar;30(3):340-349 PMID: 27834350
  3. Implications for powering biomarker discovery studies.
    J Mol Diagn. 2012 Mar-Apr;14(2):130-9 PMID: 22251612
  4. The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014.
    Ann Oncol. 2015 Feb;26(2):259-71 PMID: 25214542
  5. Intratumoral CD8(+) T/FOXP3 (+) cell ratio is a predictive marker for survival in patients with colorectal cancer.
    Cancer Immunol Immunother. 2010 May;59(5):653-61 PMID: 19908042
  6. Tumor-associated lymphocytes predict response to neoadjuvant chemotherapy in breast cancer patients.
    J Breast Cancer. 2013 Mar;16(1):32-9 PMID: 23593079
  7. Predominant infiltration of macrophages and CD8(+) T Cells in cancer nests is a significant predictor of survival in stage IV nonsmall cell lung cancer.
    Cancer. 2008 Sep 15;113(6):1387-95 PMID: 18671239
  8. Persistence of tumor-infiltrating CD8 T cells is tumor-dependent but antigen-independent.
    Cell Mol Immunol. 2011 Sep;8(5):415-23 PMID: 21666707
  9. PD-1 blockade induces responses by inhibiting adaptive immune resistance.
    Nature. 2014 Nov 27;515(7528):568-71 PMID: 25428505
  10. Prevalence of FOXP3+ regulatory T cells increases during the progression of pancreatic ductal adenocarcinoma and its premalignant lesions.
    Clin Cancer Res. 2006 Sep 15;12(18):5423-34 PMID: 17000676
  11. Prevalence and heterogeneity of KRAS, BRAF, and PIK3CA mutations in primary colorectal adenocarcinomas and their corresponding metastases.
    Clin Cancer Res. 2010 Feb 1;16(3):790-9 PMID: 20103678
  12. Development of omics-based clinical tests for prognosis and therapy selection: the challenge of achieving statistical robustness and clinical utility.
    Clin Trials. 2013 Oct;10(5):653-65 PMID: 24000377
  13. Tumor-infiltrating CD8+ lymphocytes predict clinical outcome in breast cancer.
    J Clin Oncol. 2011 May 20;29(15):1949-55 PMID: 21483002
  14. Prognostic significance of tumor-infiltrating CD8+ and FOXP3+ lymphocytes in residual tumors and alterations in these parameters after neoadjuvant chemotherapy in triple-negative breast cancer: a retrospective multicenter study.
    Breast Cancer Res. 2015 Sep 04;17:124 PMID: 26341640
  15. Histopathologic-based prognostic factors of colorectal cancers are associated with the state of the local immune reaction.
    J Clin Oncol. 2011 Feb 20;29(6):610-8 PMID: 21245428
  16. An industry statistician's perspective on PHC drug development.
    Contemp Clin Trials. 2013 Nov;36(2):624-35 PMID: 23648396
  17. A statistician's perspective on biomarkers in drug development.
    Pharm Stat. 2011 Nov-Dec;10(6):494-507 PMID: 22162336
  18. The relationship between T-lymphocyte infiltration, stage, tumour grade and survival in patients undergoing curative surgery for renal cell cancer.
    Br J Cancer. 2003 Nov 17;89(10):1906-8 PMID: 14612901
  19. Towards the introduction of the 'Immunoscore' in the classification of malignant tumours.
    J Pathol. 2014 Jan;232(2):199-209 PMID: 24122236
  20. Reliability of Prognostic and Predictive Factors Evaluated by Needle Core Biopsies of Large Breast Invasive Tumors.
    Am J Clin Pathol. 2015 Oct;144(4):555-62 PMID: 26386076
  21. Transient expression of FOXP3 in human activated nonregulatory CD4+ T cells.
    Eur J Immunol. 2007 Jan;37(1):129-38 PMID: 17154262
  22. Prognostic effect of epithelial and stromal lymphocyte infiltration in non-small cell lung cancer.
    Clin Cancer Res. 2008 Aug 15;14(16):5220-7 PMID: 18698040
  23. Automated selection of DAB-labeled tissue for immunohistochemical quantification.
    J Histochem Cytochem. 2003 May;51(5):575-84 PMID: 12704205
  24. Clinical significance of immune cell infiltration within gallbladder cancer.
    Br J Cancer. 2003 Nov 3;89(9):1736-42 PMID: 14583778
  25. Tumour-infiltrating CD8 to FOXP3 lymphocyte ratio in predicting treatment responses to neoadjuvant chemotherapy of aggressive breast cancer.
    Br J Surg. 2016 Jun;103(7):845-54 PMID: 26953091
  26. Proliferative activity of intratumoral CD8(+) T-lymphocytes as a prognostic factor in human renal cell carcinoma: clinicopathologic demonstration of antitumor immunity.
    Cancer Res. 2001 Jul 1;61(13):5132-6 PMID: 11431351
  27. Deeper examination of negative colorectal biopsies.
    Am J Clin Pathol. 2002 Mar;117(3):424-8 PMID: 11888081
  28. Tumour-infiltrating lymphocytes: A prognostic factor of PSA-free survival in patients with local prostate carcinoma treated by radical prostatectomy.
    Anticancer Res. 2005 Nov-Dec;25(6C):4435-8 PMID: 16334122
  29. Biomarkers in drug development: friend or foe? A personal reflection gained working within oncology.
    Pharm Stat. 2007 Oct-Dec;6(4):253-60 PMID: 17351904
  30. Concurrent infiltration by CD8+ T cells and CD4+ T cells is a favourable prognostic factor in non-small-cell lung carcinoma.
    Br J Cancer. 2006 Jan 30;94(2):275-80 PMID: 16421594
  31. Localization and density of immune cells in the invasive margin of human colorectal cancer liver metastases are prognostic for response to chemotherapy.
    Cancer Res. 2011 Sep 1;71(17):5670-7 PMID: 21846824
  32. The relationship between the local and systemic inflammatory responses and survival in patients undergoing resection for localized renal cancer.
    BJU Int. 2008 Sep;102(6):756-61 PMID: 18384626
  33. CD8 tumor-infiltrating lymphocytes are predictive of survival in muscle-invasive urothelial carcinoma.
    Proc Natl Acad Sci U S A. 2007 Mar 6;104(10):3967-72 PMID: 17360461
  34. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome.
    Science. 2006 Sep 29;313(5795):1960-4 PMID: 17008531
  35. Tumour-infiltrating CD8+ lymphocytes as an independent predictive factor for pathological complete response to primary systemic therapy in breast cancer.
    Br J Cancer. 2013 Nov 12;109(10):2705-13 PMID: 24129232
  36. CD4+ T cells in cancer stroma, not CD8+ T cells in cancer cell nests, are associated with favorable prognosis in human non-small cell lung cancers.
    Cancer Sci. 2003 Nov;94(11):1003-9 PMID: 14611679
  37. Considerations for the successful co-development of targeted cancer therapies and companion diagnostics.
    Nat Rev Drug Discov. 2013 Oct;12 (10 ):743-55 PMID: 24008432
  38. Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma.
    Cancer. 1996 Apr 1;77(7):1303-10 PMID: 8608507
  39. Peritumoral FOXP3⁺ regulatory T cell is sensitive to chemotherapy while intratumoral FOXP3⁺ regulatory T cell is prognostic predictor of breast cancer patients.
    Breast Cancer Res Treat. 2012 Sep;135(2):459-67 PMID: 22842982
  40. Sample size and threshold estimation for clinical trials with predictive biomarkers.
    Contemp Clin Trials. 2013 Nov;36(2):664-72 PMID: 24064355
  41. Tumor-infiltrating FOXP3+ T regulatory cells show strong prognostic significance in colorectal cancer.
    J Clin Oncol. 2009 Jan 10;27(2):186-92 PMID: 19064967
  42. Prognostic significance of T helper 1 and 2 and T cytotoxic 1 and 2 cells in patients with non-small cell lung cancer.
    Anticancer Res. 2005 May-Jun;25(3B):2027-31 PMID: 16158940
  43. Analytical and clinical evaluation of biomarkers assays: when are biomarkers ready for prime time?
    Clin Trials. 2013 Oct;10(5):666-76 PMID: 23983159
  44. Leukocyte composition of human breast cancer.
    Proc Natl Acad Sci U S A. 2012 Feb 21;109(8):2796-801 PMID: 21825174
  45. In situ cytotoxic and memory T cells predict outcome in patients with early-stage colorectal cancer.
    J Clin Oncol. 2009 Dec 10;27(35):5944-51 PMID: 19858404
  46. Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer.
    Proc Natl Acad Sci U S A. 2005 Dec 20;102(51):18538-43 PMID: 16344461
  47. CD8+ lymphocyte infiltration is an independent favorable prognostic indicator in basal-like breast cancer.
    Breast Cancer Res. 2012 Mar 15;14(2):R48 PMID: 22420471
  48. FoxP3- and CD8-positive Infiltrating Immune Cells Together Determine Clinical Outcome in Colorectal Cancer.
    Cancer Microenviron. 2013 Apr;6(1):31-9 PMID: 21732187
  49. Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer.
    Proc Natl Acad Sci U S A. 2007 Feb 27;104(9):3360-5 PMID: 17360651
  50. In situ analysis of FOXP3+ regulatory T cells in human colorectal cancer.
    J Transl Med. 2006 Dec 13;4:52 PMID: 17166272
  51. Evidence for in situ amplification of cytotoxic T-lymphocytes with antitumor activity in a human regressive melanoma.
    Cancer Res. 1993 Aug 1;53(15):3569-73 PMID: 8339262
  52. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency.
    N Engl J Med. 2015 Jun 25;372(26):2509-20 PMID: 26028255
  53. CD8(+) T lymphocytes infiltrating breast cancer: A promising new prognostic marker?
    Oncoimmunology. 2012 May 1;1(3):364-365 PMID: 22737616
  54. On the role of melanoma-specific CD8+ T-cell immunity in disease progression of advanced-stage melanoma patients.
    Clin Cancer Res. 2004 Jul 15;10(14):4754-60 PMID: 15269149
  55. The prognostic impact of M-CSF, CSF-1 receptor, CD68 and CD3 in prostatic carcinoma.
    Histopathology. 2008 Jul;53(1):30-8 PMID: 18510570
  56. Automatic nuclei segmentation in H&E stained breast cancer histopathology images.
    PLoS One. 2013 Jul 29;8(7):e70221 PMID: 23922958
  57. CD8+ tumor-infiltrating lymphocytes together with CD4+ tumor-infiltrating lymphocytes and dendritic cells improve the prognosis of patients with pancreatic adenocarcinoma.
    Pancreas. 2004 Jan;28(1):e26-31 PMID: 14707745
Article Info
Journal
PloS one
Abbr.
PLoS One
ISSN
1932-6203
Published
2018-00-00
Epub
2018-00-10
Pages
e0190158
Language
English
Region
United States
NLM ID
101285081
PMCID
PMC5761898
Subset
IM
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]